BioCentury | Oct 6, 2011
Distillery Therapeutics

Indication: Infectious disease

...vehicle. Next steps include advancing squalamine to clinical trials for viral infection. Ohr Pharmaceutical Inc.'s Evizon...
BioCentury | Jul 25, 2011
Clinical News

Ohr preclinical data

...to no signs of ocular toxicity or changes in intraocular pressure. In 2009, Ohr acquired Evizon...
BioCentury | Dec 7, 2009
Company News

Advanced Viral, Ohr endocrine, dermatology, ophthalmic news

...Evizon squalamine and trodusquemine ( MSI-1436 ) for $200,000 in August. Genaera halted development of Evizon...
BioCentury | Oct 1, 2007
Finance

3Q approvals

...arterial hypertension (PAH) Genaera (GENR) Discontinues development of Lomucin to treat cystic fibrosis (CF), and squalamine lactate...
BioCentury | Jul 9, 2007
Clinical News

Squalamine lactate: Development discontinued

...compete with marketed treatments (see BioCentury, Jan. 8). Genaera Corp. (GENR), Plymouth Meeting, Penn. Product: Squalamine lactate...
BioCentury | Jul 9, 2007
Finance

Ebb & Flow

...Lomucin, an orally absorbed antagonist of calcium-activated chloride channel (gob-5) to treat cystic fibrosis, and squalamine lactate...
BioCentury | Jul 6, 2007
Company News

Genaera ends Lomucin, squalamine trials

...GENR discontinued studies of Lomucin talniflumate for cystic fibrosis and squalamine lactate to treat prostate cancer. The...
BioCentury | Jul 2, 2007
Finance

Restructuring watch

...PTP-1B) inhibitor in preclinical development to treat obesity. In January, GENR discontinued development of Evizon squalamine lactate...
BioCentury | Apr 16, 2007
Company News

Genaera endocrine, inflammation news

...IL-9) in Phase II testing to treat asthma. In January, GENR discontinued development of Evizon squalamine lactate...
BioCentury | Apr 2, 2007
Finance

Restructuring watch

...ended 12/31/06 1/3/07 Genaera (GENR) 30% to ~25 $33.8 1.5 12/31/06 $22.8 Discontinues development of Evizon...
Items per page:
1 - 10 of 28